Nilstat

Pruritus Vulvae, Trichomonas Vaginitis, Pruritus Ani + 13 more
Treatment
18 Active Studies for Nilstat

What is Nilstat

NystatinThe Generic name of this drug
Treatment SummaryNystatin is a medication used to treat fungal infections caused by yeast and certain types of fungi. It is produced by a strain of bacteria called Streptomyces noursei and is similar to Amphotericin B. Nystatin is most effective when applied directly to the infected area, as it does not get absorbed by the body when taken orally or topically. It is primarily used to treat skin, mucous membrane, and gastrointestinal fungal infections.
Nystatinis the brand name
image of different drug pills on a surface
Nilstat Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Nystatin
Nystatin
1979
252

Effectiveness

How Nilstat Affects PatientsNystatin is an antifungal medication used to treat fungal infections caused by certain types of yeast. It works by breaking down the cell wall of the yeast, preventing it from growing. It has limited effectiveness against other types of organisms, including bacteria, protozoa, and viruses. It is not suitable for use in the body, so it is only used to treat external and gastrointestinal infections. Resistance to nystatin is rare in _Candida albicans_ but more common in other species of _Candida_.
How Nilstat works in the bodyNystatin works by creating a hole or pore in the cell membrane of fungi. This pore changes the membrane's permeability, which causes the cell's contents to leak out and disrupts the proper functioning of the cell. Nystatin is a selective drug because it binds to an ingredient in fungal cell walls, which is different than the ingredient in mammal cell walls.

When to interrupt dosage

The prescribed dose of Nilstat is contingent upon the diagnosed state, such as cutaneous candidiasis, Skin candida and corticosteroid-responsive dermatoses. The amount also changes according to the mode of delivery (e.g. Insert or Insert - Vaginal) outlined in the following table.
Condition
Dosage
Administration
Skin candida
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Skin Diseases
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Candidiasis, Oral
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Low; Birthweight
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Pruritus Ani
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Candidiasis
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Anal candidiasis
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
cutaneous candidiasis
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Urinary Tract Infection (UTI)
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Candida albicans
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Pruritus Vulvae
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Trichomonas Vaginitis
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Candidiasis, Vulvovaginal
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Candidiasis, Invasive
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Candidiasis, Vulvovaginal
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical
Yeast Infection
100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg
Suspension, , Oral, Suspension - Oral, Topical, Ointment, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Vaginal, Suppository, Suppository - Vaginal, Cream - Vaginal, Liquid, Liquid - Oral, Tablet, Tablet - Vaginal, Tablet - Oral, Solution / drops, Solution / drops - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert, Insert - Vaginal, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Warnings

Nilstat has one contraindication, hence it should not be taken when encountering any of the conditions noted in the below table.Nilstat Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Nystatin may interact with Pulse Frequency
There are 20 known major drug interactions with Nilstat.
Common Nilstat Drug Interactions
Drug Name
Risk Level
Description
Revefenacin
Major
Nystatin may decrease the excretion rate of Revefenacin which could result in a higher serum level.
Ambrisentan
Minor
The excretion of Ambrisentan can be decreased when combined with Nystatin.
Asunaprevir
Minor
The excretion of Asunaprevir can be decreased when combined with Nystatin.
Atorvastatin
Minor
The excretion of Atorvastatin can be decreased when combined with Nystatin.
Atrasentan
Minor
The excretion of Atrasentan can be decreased when combined with Nystatin.
Nilstat Toxicity & Overdose RiskThe lowest toxic dose of nystatin in rats found to be 10 g/kg. Taking a large dose of nystatin (more than 5 million units per day) may cause nausea and gastrointestinal distress, but there have been no reports of serious harm.

Nilstat Novel Uses: Which Conditions Have a Clinical Trial Featuring Nilstat?

39 active trials are currently underway to assess the potential of Nilstat in the management of Urinary Tract Infection (UTI), Yeast Infection and Pruritus Ani.
Condition
Clinical Trials
Trial Phases
Pruritus Ani
0 Actively Recruiting
Candida albicans
0 Actively Recruiting
Skin candida
0 Actively Recruiting
Anal candidiasis
0 Actively Recruiting
Candidiasis, Invasive
4 Actively Recruiting
Phase 3, Not Applicable
Trichomonas Vaginitis
2 Actively Recruiting
Phase 2, Phase 4
Candidiasis, Oral
0 Actively Recruiting
Yeast Infection
0 Actively Recruiting
Low; Birthweight
2 Actively Recruiting
Not Applicable
Skin Diseases
0 Actively Recruiting
cutaneous candidiasis
0 Actively Recruiting
Candidiasis
0 Actively Recruiting
Candidiasis, Vulvovaginal
2 Actively Recruiting
Not Applicable, Phase 3
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Pruritus Vulvae
0 Actively Recruiting
Candidiasis, Vulvovaginal
0 Actively Recruiting

Nilstat Reviews: What are patients saying about Nilstat?

4Patient Review
4/21/2014
Nilstat for Candida Fungus Infection of Mouth, Skin, Nails or Vagina
This treatment is effective.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nilstat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How quickly does NILSTAT work?

"You will take the nystatin liquid four times a day, after meals and before bedtime. It is important not to eat or drink for thirty minutes after taking the liquid. Two days is usually when the nystatin starts working. Even after your condition improves, you will need to continue taking or using nystatin for an additional two days."

Answered by AI

How long do you use NILSTAT for?

"If you're using NILSTAT and don't see improvement within two weeks, or if symptoms return shortly after stopping treatment, you should contact your doctor."

Answered by AI

Can you get NILSTAT over the counter?

"You must speak to a pharmacist before using this product."

Answered by AI

What is NILSTAT used for?

"NILSTAT is a medication used to treat intestinal candidiasis, also known as thrush. This is an infection in your gut caused by the Candida fungus. NILSTAT is classified as an antifungal agent, meaning it works by damaging the cell wall of the Candida fungus, causing it to die."

Answered by AI

Clinical Trials for Nilstat

Have you considered Nilstat clinical trials? We made a collection of clinical trials featuring Nilstat, we think they might fit your search criteria.Go to Trials
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA
The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.
Phase 4
Recruiting
Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)
Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO
Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.
Phase 4
Recruiting
University of MissouriKevin M Klifto, DO, PharmD
Image of Children's Hospital of Philadelphia in Philadelphia, United States.

Antifungal Therapy Duration for Candidemia in Children

120 - 18
All Sexes
Philadelphia, PA
The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups. Participants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.
Recruiting
Has No Placebo
Children's Hospital of Philadelphia (+17 Sites)Brian Fisher, DO
Have you considered Nilstat clinical trials? We made a collection of clinical trials featuring Nilstat, we think they might fit your search criteria.Go to Trials
Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Data Accountability + Doula Support for Maternal Health Disparities

12 - 99
Female
Chapel Hill, NC
This project-also known as "Accountability for Care through Undoing Racism \& Equity for Moms" or ACURE4Moms-aims to reduce Black-White maternal health disparities using multi-level interventions designed to decrease bias in prenatal care, improve care coordination, and increase social support. ACURE4Moms is a pragmatic 4-arm cluster randomized controlled trial conducted with 39 prenatal practices across North Carolina. Practices have been randomly assigned to receive either: Arm 1 (Standard Care): North Carolina Medicaid Care management for high-risk pregnancies; Arm 2 (Data Accountability and Transparency): North Carolina Medicaid Care Management + Practice-level Data Accountability interventions; Arm 3 (Community-Based Doula Support): North Carolina Medicaid Care Management + Community-Based Doula support intervention for high-risk patients during pregnancy and postpartum; or Arm 4 (Data Accountability and Transparency + Community-Based Doula Support): North Carolina Medicaid Care Management + Both Arms 2 and 3 interventions. During each practice's 2-year intervention period, the practice will initiate prenatal care for \~750-1,500 patients (up to 60,000 patients total), whose outcomes the investigators will follow and compare between arms until all these patients have reached 1-year post-delivery.
Recruiting
Has No Placebo
University of North Carolina at Chapel HillJennifer H Tang, MD, MSCR
Image of Houston Methodist Hospital - Texas Medical Center in Houston, United States.

Fosmanogepix for Candida Blood Infection

18+
All Sexes
Houston, TX
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosmanogepix tablets. One-third of all patients will receive a standard of care regimen of caspofungin Intravenous (IV) infusion followed by optional fluconazole capsules. Fosmanogepix or caspofungin will first be given as an Intravenous (IV) infusion directly into a vein in the arm each day at the study clinic. Fosmanogepix tablets or fluconazole capsules will be taken orally by mouth daily either at the study clinic, or at home if patients are well enough to be discharged from the hospital. The treatment effect in patients receiving fosmanogepix to those receiving caspofungin/ fluconazole will be compared. The primary aim is to show that fosmanogepix is not inferior (not worse) to caspofungin/ fluconazole with a noninferiority margin of 15%. The duration of study treatment and number of study visits will vary depending on how long the patient will be treated for the infection. Treatment will continue for a maximum of 6 weeks depending on when the infection is cleared and whether other symptoms related to the infection have improved. There will also be a follow-up visit 6 weeks after the study treatment was stopped.
Phase 3
Recruiting
Houston Methodist Hospital - Texas Medical Center (+12 Sites)Manuel Häckl, MDBasilea Pharmaceutica
Have you considered Nilstat clinical trials? We made a collection of clinical trials featuring Nilstat, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security